Mirae Asset Global Investments
ZVRA icon

Mirae Asset Global Investments’s Zevra Therapeutics ZVRA Stock Holding History

Mirae Asset Global Investments’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.9K Sell
2,644
-292
-10% -$3.25K ﹤0.01% 1400
2026
Q1 		$27.4K Buy
2,936
+200
+7% +$1.8K ﹤0.01% 1389
2025
Q4 		$24.5K Buy
2,736
+566
+26% +$5.35K ﹤0.01% 1509
2025
Q3 		$20.6K Buy
2,170
+58
+3% +$582 ﹤0.01% 1488
2025
Q2 		$18.6K Buy
2,112
+326
+18% +$2.65K ﹤0.01% 1409
2025
Q1 		$14K Buy
1,786
+7
+0.4% +$56 ﹤0.01% 1429
2024
Q4 		$14.9K Buy
+1,779
New +$15.2K ﹤0.01% 1462
2024
Q1 		– Sell
-19,072
Closed -$125K – 2670
2023
Q4 		$125K Hold
19,072
– – ﹤0.01% 2424
2023
Q3 		$91.9K Hold
19,072
– – ﹤0.01% 2474
2023
Q2 		$97.3K Buy
+19,072
New +$103K ﹤0.01% 2517

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Mirae Asset Global Investments's ZVRA Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Zevra Therapeutics (ZVRA) stake by 9.9% in Q2 2026, selling an estimated $3.25K and leaving 2,644 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1400.

Mirae Asset Global Investments first reported a position in ZVRA in Q2 2023 and has held it in 10 quarters since. The position peaked at $125K in Q4 2023. 54 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Mirae Asset Global Investments held 2,644 shares of Zevra Therapeutics worth $37.9K as of Q2 2026.
  • Mirae Asset Global Investments sold 292 Zevra Therapeutics shares in Q2 2026, an estimated $3.25K.
  • Zevra Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1400 holding.
  • Mirae Asset Global Investments first reported a position in Zevra Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • Mirae Asset Global Investments's Zevra Therapeutics position peaked at $125K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.